Q32 Bio (QTTB) vs Sutro Biopharma (STRO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Q32 Bio (QTTB) has outperformed Sutro Biopharma (STRO) over the past year, gaining 170.6% versus a gain of 80.2%. Over five years, STRO leads with a -91.9% price change compared with -92.8% for QTTB. Sutro Biopharma is the larger company by market cap ($254.0 million vs $240.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | QTTB | STRO |
|---|---|---|
| Share price | $8.09 | $15.32 |
| Market cap | $240.83M | $254.02M |
| 1-day change | +1.25% | +4.50% |
| YTD return | +143.67% | +32.41% |
| 1-year return | +170.57% | +80.24% |
| 5-year return | -92.75% | -91.93% |
| P/E ratio (TTM) | 2.57 | — |
| EPS (TTM) | $3.15 | $-17.28 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $23.57 | $43.85 |
| 52-week low | $1.91 | $7.15 |
| Distance from 52-week high | -65.68% | -65.06% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +389.49% | +208.29% |
| Average volume | 1.38M | 286.74K |
| Shares outstanding | 29.77M | 16.58M |
| Employees | 22 | 128 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- QTTB has outperformed STRO by 90.3 percentage points over the past year.
About Q32 Bio
QTTB stock →Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody which completed Phase 2a clinical trials, designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic dermatitis and alopecia areata.
Health Care · Biotechnology: Pharmaceutical Preparations · 22 employees
About Sutro Biopharma
STRO stock →Sutro Biopharma, Inc. operates as an oncology company.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 128 employees
QTTB vs STRO FAQ
Which is bigger, Q32 Bio or Sutro Biopharma?
Sutro Biopharma (STRO) is larger, with a market capitalization of $254.02M compared with $240.83M for Q32 Bio (QTTB).
Which stock has performed better over the past year, QTTB or STRO?
QTTB returned +170.57% over the past 12 months, compared with +80.24% for STRO (price return, excluding dividends). Past performance does not predict future results.
Are Q32 Bio and Sutro Biopharma in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Q32 Bio and Biotechnology: Biological Products (No Diagnostic Substances) for Sutro Biopharma.